Isomorphic Labs is a London-based AI drug design company spun out from DeepMind, focused on advancing AI-designed drug candidates to clinical trials.
Isomorphic Labs is discussing a $5 billion funding round at a $50 billion valuation as it prepares to begin its first clinical trials.
Isomorphic Labs has appointed Dr. Ben Wolf as Chief Medical Officer and established a new US presence in Cambridge, Massachusetts, announced in a press release.
Isomorphic Labs, a spinout from DeepMind, has raised $600 million in its first external funding round led by Thrive Capital, with participation from Google Ventures and Alphabet.
Daily report covering major AI developments and industry news, with both top stories and complete market updates